Therapeutic-dose heparin appears to benefit noncritically-ill COVID-19 patients, but it does not reduce deaths or other adverse endpoints compared with usual-care thromboprophylaxis if it’s initiated ...
Now reported in the Journal are the results of an international, multiplatform, randomized clinical trial that combined data from patients who were enrolled in one conventional randomized trial (ACTIV ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results